Table 2.
Univariate and multivariate analysis of variables correlated with DFS in HR-positive patients within and after 5 years.
| Variables | Univariate analysis | Multivariate analysis | ||||||
|---|---|---|---|---|---|---|---|---|
| DFS (within 5 years) | DFS (after 5 years) | DFS (within 5 years) | DFS (after 5 years) | |||||
| Hazard Ratio (95% CI) | p-Value | Hazard Ratio (95% CI) | p-Value | Hazard Ratio (95% CI) | p-Value | Hazard Ratio (95% CI) | p-Value | |
| Age, years | 0.06 | 0.189 | 0.061 | 0.344 | ||||
| <40 | Reference | Reference | Reference | Reference | ||||
| 40–49 | 0.51 (0.27–0.98) | 0.043 | 0.23 (0.05–1.03) | 0.054 | 0.55 (0.27–1.14) | 0.11 | 0.20 (0.04–0.93) | 0.04 |
| 50–59 | 0.38 (0.20–0.73) | 0.004 | 0.58 (0.16–2.16) | 0.416 | 0.33 (0.16–0.69) | 0.003 | 2.43 (0.04–1.70) | 0.154 |
| 60–69 | 0.53 (0.26–1.10) | 0.087 | 0.91 (0.26–3.24) | 0.888 | 0.49 (0.21–1.13) | 0.093 | 0.25 (0.03–2.05) | 0.197 |
| >=70 | 0.35 (0.12–1.00) | 0.05 | 1.37 (0.31–6.12) | 0.683 | 0.48 (0.14–1.64) | 0.241 | 0.25 (0.03–2.35) | 0.224 |
| Menopausal status | 0.648 | 0.045 | 0.128 | |||||
| Premenopausal | Reference | Reference | Reference | |||||
| Postmenopausal | 0.91 (0.60–1.37) | 0.648 | 2.53 (1.02–6.28) | 0.045 | 3.82 (0.68–21.47) | 0.128 | ||
| Histological type | 0.096 | 0.029 | ||||||
| No special type | Reference | Reference | ||||||
| Invasive lobular | 2.57 (0.79–8.37) | 0.116 | 12.80 (1.50–109.02) | 0.02 | ||||
| Other | 0.56 (0.25–1.23) | 0.149 | 1.03 (0.37–2.84) | 0.959 | ||||
| Grade | 0.072 | 0.463 | 0.016 | |||||
| Grade I | Reference | Reference | Reference | |||||
| Grade II | 0.59 (0.27–1.31) | 0.193 | 3.24 (0.43–24.60) | 0.257 | 0.65 (0.26–1.63) | 0.358 | ||
| Grade III | 1.10 (0.47–2.59) | 0.826 | 4.99 (0.58–42.74) | 0.142 | 1.54 (0.55–4.32) | 0.417 | ||
| Unknown | 0.60 (0.20–1.80) | 0.36 | 1.94 (0.12–31.08) | 0.639 | 0.25 (0.04–1.54) | 0.134 | ||
| T stage | 0.841 | 0.435 | ||||||
| T0/is/1 | Reference | Reference | ||||||
| T2 | 1.08 (0.71–1.65) | 0.721 | 1.15 (0.46–2.88) | 0.768 | ||||
| T3 | 0.74 (0.32–1.73) | 0.484 | 7.57 (0.99–58.00) | 0.052 | ||||
| T4 | 1.38 (0.19–10.06) | 0.751 | / | 0.991 | ||||
| N stage | 0.008 | 0.371 | < 0.001 | |||||
| N0 | Reference | Reference | Reference | |||||
| N1 | 1.53 (0.91–2.58) | 0.11 | 1.06 (0.36–3.11) | 0.912 | 1.97 (1.10–3.53) | 0.023 | ||
| N2 | 1.08 (0.59–1.98) | 0.8 | 2.86 (0.89–9.12) | 0.077 | 1.14 (0.56–2.33) | 0.722 | ||
| N3 | 2.58 (1.40–4.75) | 0.002 | 2.58 (0.57–11.80) | 0.221 | 4.17 (2.05–8.46) | < 0.001 | ||
| HER2 status | 0.613 | 0.008 | 0.01 | |||||
| HER2-zero | Reference | Reference | Reference | |||||
| HER2-low | 0.875 (0.52–1.47) | 0.613 | 0.31 (0.13–0.73) | 0.008 | 0.31 (0.13–0.75) | 0.01 | ||
| Ki-67 | 0.13 | 0.294 | 0.032 | |||||
| <15% | Reference | Reference | Reference | |||||
| 15%–30% | 1.15 (0.71–1.88) | 0.575 | 2.47 (0.80–7.69) | 0.118 | 1.67 (0.93–3.01) | 0.087 | ||
| >30% | 1.75 (0.99–3.10) | 0.055 | 2.00 (0.53–7.46) | 0.305 | 2.64 (1.28–5.45) | 0.009 | ||
| TOP2A | 0.162 | 0.2 | ||||||
| <30% | Reference | Reference | ||||||
| 30%–60% | 1.50 (0.90–2.49) | 0.123 | 0.92 (0.49–1.73) | 0.803 | ||||
| >60% | 0.34 (0.05–2.46) | 0.284 | 0.14 (0.02–1.21) | 0.074 | ||||
| Endocrine therapy | 0.621 | 0.028 | 0.085 | |||||
| No/Unknown | Reference | Reference | Reference | |||||
| Yes | 0.87 (0.50–1.51) | 0.621 | 0.30 (0.10–0.88) | 0.028 | 0.37 (0.12–1.15) | 0.085 | ||
| Radiotherapy | 0.496 | 0.64 | ||||||
| No/Unknown | Reference | Reference | ||||||
| Yes | 1.15 (0.77–1.74) | 0.496 | 1.23 (0.52–2.89) | 0.64 | ||||
| Chemotherapy | 0.298 | 0.267 | ||||||
| No/Unknown | Reference | Reference | ||||||
| Yes | 1.27 (0.81–1.98) | 0.298 | 1.77 (0.65–4.83) | 0.267 | ||||
DFS, disease-free survival; HR, hormone receptor; HER2, human epiderma growth factor receptor 2; TOP2A, topoisomerase II alpha.